VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ANGO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ANGOAngioDynamics, Inc.
$11.49$468M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ANGO logo

AngioDynamics, Inc.

ANGO
NASDAQ · Medical Devices
$11.49
At close - Nov 17, 4:00 PM EST - USD
Market Cap$475M
P/E-14.7x
52W High$16.29
Volume304.46K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2027Q1

Gross Margin Inflection Battles Persistent Cash Burn

AngioDynamics appears to be at an early-stage turnaround inflection: quarterly revenue growth has recovered from -22.1% in 2024Q4 to the +7-9% range across 2026, while gross margin expanded roughly 670 basis points from 52.7% in 2025Q4 to 59.4% in 2027Q1, narrowing the operating loss to -$2.4M (-3.0% margin) — the…

GrowthExpanding
ProfitabilityWeak
ValuationExpensive
TechnicalsWeak
Explore valuation models
MARKET ACTION

ANGO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

10/12 Beats

EPS beat 10 of last 12 quarters

02

Valuation risk

-146% Peers

P/E is 146% below peer median

03

Market leadership

RS 45 · Lag

Laggard (Underperforming 55% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystConfirmed earnings · Jan 6

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ANGO-9.38%
S&P 500 (^GSPC)+7.21%
1-Year Return
ANGO-3.53%
S&P 500 (^GSPC)+10.03%
3-Year Return
ANGO+68.48%
S&P 500 (^GSPC)+59.35%
5-Year Return
ANGO-61.06%
S&P 500 (^GSPC)+53.64%

Growth & profitability

Annual revenue & EPS trend
Revenue FY26
$320M+9.5% YoY
Net income FY26
-$37M-8.1% YoY
Free cash flow FY26
$508K+103.5% YoY
Operating margin FY26
-12.5%+1.2 pts YoY
ROIC (FY26)-23.6%
Avg ROIC 5Y-22.8%
ROE (TTM)-19.2%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate10/12 (83%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 8, 2026
-$0.04+64.4%
vs -$0.11
$81M+0.5%
vs $81M
Q3 2026
Jul 14, 2026
-$0.07+36.4%
vs -$0.11
$87M+7.9%
vs $80M
Q2 2026
Apr 2, 2026
-$0.07+36.4%
vs -$0.11
$78M+2.2%
vs $77M
Q1 2026
Jan 6, 2026
-$0.15-50.0%
vs -$0.10
$79M+3.9%
vs $76M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·Nov 6, 2026
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as of November 2, 2026. On November 2, 2026 (the “Grant Date”), as an inducement.

Business Wire·Oct 21, 2026
AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in.

Seeking Alpha·Oct 15, 2026
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.

GuruFocus·Oct 14, 2026
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste

Filtered for AngioDynamics, Inc.More Headlines
04

Compare before deciding

Benchmark ANGO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for AngioDynamics, Inc. (ANGO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ANGO logoANGOAngioDynamics, Inc.Current
$11.49$474.91M-14.669.46%-10.12%-19.25%—
NVCR logoNVCRNovocure Ltd
$11.14$1.29B-10.698.28%-16.78%-35.81%—
ATRC logoATRCAtriCure, Inc.
$55.02$2.8B184.2014.88%2.52%2.93%—
MMSI logoMMSIMerit Medical Systems, Inc.
$84.49$5.04B31.8611.66%9.94%9.65%—
ITGR logoITGRInteger Holdings Corporation
$126.97$4.31B42.377.57%5.68%6.02%—
CNMD logoCNMDCONMED Corporation
$48.39$1.45B19.855.16%5.36%7.07%1.64%

Compare ANGO vs Peers

AngioDynamics, Inc. (ANGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for ANGO.

Scale Benchmark

vs ABT

Larger-name benchmark to compare ANGO against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ATRC, MMSI, ITGR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ANGO SEC Filings & Documents

AngioDynamics, Inc. (ANGO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 8, 2026·SEC

Material company update

Oct 8, 2026·SEC

Material company update

Jul 14, 2026·SEC

10-K Annual Reports

4
FY 2026

Jul 14, 2026·SEC

FY 2025

Jul 18, 2025·SEC

FY 2024

Jul 25, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 8, 2026·SEC

FY 2026

Apr 2, 2026·SEC

FY 2026

Jan 6, 2026·SEC

Get notified when ANGO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ANGO Frequently Asked Questions

AngioDynamics, Inc. (ANGO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is AngioDynamics, Inc.'s revenue?

AngioDynamics, Inc. (ANGO) reported $325.4M in revenue over the trailing twelve months. Revenue was $320.2M in fiscal year 2026. That is 936% more than the $30.9M of fiscal year 2002.

How fast is AngioDynamics, Inc. growing?

AngioDynamics, Inc. (ANGO) grew revenue by 8.2% over the trailing twelve months, compared with the twelve months before.

Is ANGO profitable?

No. AngioDynamics, Inc. (ANGO) reported a net loss of $32.9M over the trailing twelve months.

Dividend & Returns
What is ANGO's return on equity?

AngioDynamics, Inc. (ANGO) had a return on equity (ROE) of -19.2% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is AngioDynamics, Inc.'s free cash flow?

AngioDynamics, Inc. (ANGO) generated $1.4M in free cash flow over the trailing twelve months.

What if you invested $1,000 in ANGO back in 2002?

Total return calculator · dividends reinvested · 24+ years of data

See returns →